ライフサイエンスコーパス: antimitotic agent

1 natural product hemiasterlin and is a potent antimitotic agent.

2 ed hydroxyphenstatin, a potent antitumor and antimitotic agent.

3 de a molecular marker to predict response to antimitotic agents.

4 ase in caspase-3/7 activation in response to antimitotic agents.

5 s and cancers that are resistant to standard antimitotic agents.

6 n of a series of triazole-based compounds as antimitotic agents.

7 d a great deal of interest as a new class of antimitotic agents.

8 uld affect the sensitivity of tumor cells to antimitotic agents.

9 ld enhance traditional and second-generation antimitotic agents.

10 es with greater efficacy than currently used antimitotic agents.

11 agents that differed in this respect was the antimitotic agents.

12 poptosis in neuroblastoma cells treated with antimitotic agents.

13 ermeability relative to many clinically used antimitotic agents.

14 lin binding of the Vinca alkaloids and other antimitotic agents, (2) proximity to stretches of amino

15 By suppressing APC(Cdc20), antimitotic agents activate the spindle-assembly checkpo

16 fanilamide (GB-II-5), is a potent, selective antimitotic agent against kinetoplastid parasites.

17 agent in those tumors resistant to existing antimitotic agents and those dependent on Hedgehog pathw

18 yins A and B and eleutherobin (coral-derived antimitotic agents) and of compound 1, an analogue of sa

19 Taxol and other antimitotic agents are frontline chemotherapy agents but

20 (TP53, best known as p53) in the presence of antimitotic agents, as determined by cytofluorometric an

21 and phomopsin A have been found to be potent antimitotic agents, causing cell death at picomolar or l

22 Topical treatments of grafted HSE with the antimitotic agent colchicine select for keratinocyte pro

23 nd-specific reversibility characteristics of antimitotic agents contribute to interactions between ce

24 hesis of the potent microtubule-stabilizing, antimitotic agent (+)-discodermolide is described.

25 The interaction of the antimitotic agent estramustine with bovine microtubule p

26 Paclitaxel (Taxol), a naturally occurring antimitotic agent, has shown significant cell-killing ac

27 Paclitaxel (Taxol), a naturally occurring antimitotic agent, has shown significant cell-killing ac

28 B-II-5, compound 3), a new antikinetoplastid antimitotic agent, have been synthesized and evaluated.

29 TI-286, a synthetic analogue of the peptidic antimitotic agent hemiasterlin, to tubulin is proposed.

30 ifiable, compound-specific characteristic of antimitotic agents in general.

31 inhibition was specifically synergistic with antimitotic agents in killing cancer cells that had unde

32 Alternatively, exposure to antimitotic agents just after neural tube closure could

33 remarkably also reverse tumor resistance to antimitotic agents mediated via the P-glycoprotein efflu

34 ocking proliferation of these cells with the antimitotic agent mitomycin C.

35 D30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (

36 neration synthesis of the exceedingly potent antimitotic agent N(14)-desacetoxytubulysin H (1) as wel

37 riety of stimuli, including the DNA-cleaving antimitotic agent, neocarzinostatin (NCS).

38 one and in combination with DNA-damaging and antimitotic agents on human cancer cells.

39 was also inhibited by bullatacin and various antimitotic agents (podophyllotoxin, vinblastine, and co

40 Combinations of EM with other antimitotic agents such as docetaxel are synergistic in

41 dentify putative biomarkers of resistance to antimitotic agents such as paclitaxel and monomethyl-aur

42 ally distinct from those of well-established antimitotic agents such as taxol.

43 Chemotherapy of prostate cancer with antimitotic agents such as vinblastine and doxorubicin i

44 ctiveness of this drug exceeds that of other antimitotic agents, suggesting it may have an additional

45 nblastine, or dolastatin 10 (another peptide antimitotic agent that depolymerizes microtubules) but w

46 Vinblastine is an antimitotic agent that has been used extensively in canc

47 Compounds of this series are promising novel antimitotic agents that have the potential for treating

48 Antimitotic agents that interfere with microtubule forma

49 Paclitaxel (Taxol) and the epothilones are antimitotic agents that promote the assembly of mammalia

50 potency against GC3/c1, LYC5 cells, and the antimitotic agent vincristine.

51 model, suggesting that 3b is a promising new antimitotic agent with clinical potential.

52 model, suggesting that 4l is a promising new antimitotic agent with clinical potential.

53 lb/c mice, suggesting that 3c could be a new antimitotic agent with clinical potential.

54 sulfonamides are a novel promising class of antimitotic agents with clinical development potential.